Abstract

Tobramycin (TOBI® or TOBI PODHALER®) in Ventilator Associated Pneumonia: An Overview

Despite the fact that Ventilator Associated Pneumonia (VAP) has a high death rate, it is not yet defined very well. Mortality in patients with lung injury on mechanical ventilation is estimated as 24% in patients 15-19 years and 60% in patients 85 years or older. Very few studies have reported the use of tobramycin (TOBI® or Tobi Podhaler®) in VAP management. However, the use of such antibiotics for treatment of VAP is equivocal and no clinical evidences reported. Tobi Podhaler® contains active substance of tobramycin, which is available as capsules (28 mg). Tobi Podhaler® can be used as a hand-held device which suppresses the chronic lung infections caused by P. aeruginosa in patients aged >6 years. The recommended dose is four capsules twice a day in adults and children older than 6 years of age. It can be also used to treat Cystic Fibrosis (CF). This review highlights the advantages of treatment with TOBI (Tobi Podhaler®) in VAP patients and also a note on inhaled antibiotics in management of chronic respiratory infections.


Author(s):

Dhilleswara Rao V



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Recommended Conferences
Flyer image
Abstracted/Indexed in
  • Google Scholar
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Publons
  • MIAR
  • ResearchGate
  • University Grants Commission
  • Secret Search Engine Labs

tempobet

tempobet giriş

tempobet giriş

tipobet süpertotobet yeni adres süperbahis 747 güvenilir bahis siteleri telefonda sex sohbet